KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.

Huaiyuan Xu, Jinxin Hu, Yun Zhang, Aihua Zhuang, Yingchun Zhang, Jibin Li, Hao Wu, Guohui Song, Chuanquan Deng, Hongmin Chen, Weiqing Chen, Chuangzhong Deng, Anqi Wang, Huixiong Feng, Jinchang Lu, Qinglian Tang, Xiaojun Zhu, Jin Wang

Clin Cancer Res 32(11) 2198-2205

PMID41504634
PMCIDPMC13223540
DOI10.1158/1078-0432.CCR-25-3128
发表日期2026-01-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT). PATIENTS AND METHODS: In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety. RESULTS: From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01-0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05). CONCLUSIONS: PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs. See related commentary by Dossa et al., p. 2127.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2. PFS and subgroup analysis. A, Kaplan–Meier estimates of PFS. Disease progression was identified by the investigators and included imaging-based progression according to RECIST 1.1 and clinical progression. Tick marks indicate censored data. B, Forest plot of PFS in prespecified subgroups. Disease progression was identified by the investigators and included imaging-based progression according to RECIST 1.1 and clinical progression. NE, not evaluated.

A

PFS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Trial profile.
非 KM Figure
Figure 3Figure 3. Tumor responses and clinical outcomes. A, Waterfall plots of the percentage change in tumor size from baseline, as assessed by RECIST v1.1. Each bar represents a patient, with dashed lines indicating partial response (30% decrease) and progressive disease (20% increase). B, Swimmer plots of the duration of response and clinical outcomes in each group.
非 KM Figure